This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Epidemiology

Authoring team

  • peak incidence of non-Hodgkin's lymphoma occurs between 50 and 70 years (67% of of cases occur in patients aged over 60 years). However all ages can be affected (1)
  • in the UK;
    • NHL is the seventh most frequently diagnosed cancer (2)
    • there is a very small male predominance compared to females
    • there are around 13,600 new non-Hodgkin lymphoma cases every year, that's 37 every day, accounting for 4% of all new cancer cases (2017-2019) (1)
    • there are 5,000 non-Hodgkin lymphoma deaths every year (2021-2023)
    • since the early 1990s, non-Hodgkin lymphoma incidence rates have increased by almost a third (30%) in the UK (1)
  • in Western Europe and the USA non-Hodgkin's lymphomas account for 55-60% of all malignant lymphomas
  • presenting features include lymphadenopathy, hepatosplenomegaly, weight loss, fatigue and night sweats
  • 40% of patients present with tumour outside lymph glands

Reference:

  1. Cancer Research UK. Non Hodgkin's Lymphoma statistics 2025 (online)
  2. NICE. Non-Hodgkin’s lymphoma: diagnosis and management. NICE guideline NG52. Published July 2016

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2026 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.